Denes V. Agoston, MD, Ph.D.

Denes V. Agoston, MD, Ph.D.

Denes Agoston

Name: Denes V. Agoston, MD, Ph.D.

Department of Primary Appointment: Anatomy, Physiology & Genetics
Position: USU Faculty
Title: Professor

Research Interests:
Experimental and Clinical Neurobiology of Traumatic Brain Injury

Email: (link sends e-mail)
Office Phone: (301) 295-3200

Department Website
PubMed Listing



  • M.D. University Medical School Szeged, Hungary;
  • Max-Planck-Fellow, Max-Planck-Institute for Biophysical Chemistry, Gottingen, Germany; 
  • DFG Fellow at the National Institute of Mental Health, NIH, Bethesda, MD, USA;
  • Ph.D. Max-Planck-Institute for Biophysical Chemistry, Gottingen, Germany & Hungarian National Academy, Budapest, Hungary;
  • Visiting Scientist, National Institute of Child Health and Human Development, NIH, Bethesda, MD, USA

The main goal of the work in the Agoston Laboratory is to narrow the gap between experimental and clinical Traumatic Brain Injury (TBI) research. We believe that by reducing existing incongruities we contribute saving lives and significantly improving the quality of life after TBI.

The Laboratory employs various models and integrated analytical methods including proteomics, histology and neurobehavioral tests enabling to monitor molecular, cellular and functional changes during the various phases of the disease. The Laboratory has developed several clinical collaborations focusing on the development and validation of protein biomarkers and molecular imaging in the context of disease progression and patient outcome.

We have identified specific molecular and cellular changes that contribute and/or cause the observed neurobehavioral impairments after TBI. Among them, neuroinflammation has emerged as a critical component of the secondary injury process. Our experimental work has shown that early anti-inflammatory treatment can prevent the development of long-term neurobehavioral deficiencies.

Current studies include determining the pathobiology of mild repeated TBI with the goal of developing diagnostic and therapeutic tools to improve outcome and to prevent adverse conditions such as Chronic Traumatic Encephalopathy.

Selected 2011-2012 Publications